BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20347734)

  • 1. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing.
    Abate E; DeMeester SR; Zehetner J; Oezcelik A; Ayazi S; Costales J; Banki F; Lipham JC; Hagen JA; DeMeester TR
    J Am Coll Surg; 2010 Apr; 210(4):428-35. PubMed ID: 20347734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
    Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
    Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
    Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
    Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
    Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
    Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease.
    Stiles BM; Mirza F; Coppolino A; Port JL; Lee PC; Paul S; Altorki NK
    Ann Thorac Surg; 2011 Aug; 92(2):491-6; discussion 496-8. PubMed ID: 21704291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
    Mariette C; Taillier G; Van Seuningen I; Triboulet JP
    Ann Thorac Surg; 2004 Oct; 78(4):1177-83. PubMed ID: 15464466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of laparoscopic-assisted transhiatal esophagectomy for adenocarcinoma of the esophagus and esophago-gastric junction.
    Montenovo MI; Chambers K; Pellegrini CA; Oelschlager BK
    Dis Esophagus; 2011 Aug; 24(6):430-6. PubMed ID: 21309915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy.
    Nigro JJ; DeMeester SR; Hagen JA; DeMeester TR; Peters JH; Kiyabu M; Campos GM; Oberg S; Gastal O; Crookes PF; Bremner CG
    J Thorac Cardiovasc Surg; 1999 May; 117(5):960-8. PubMed ID: 10220691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone.
    Achiam MP; Jensen LB; Larsson H; Jensen LS; Larsen AC; Holm J; Svendsen LB
    Scand J Surg; 2016 Mar; 105(1):22-8. PubMed ID: 25794689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics, biologic behavior, and survival after esophagectomy are similar for adenocarcinoma of the gastroesophageal junction and the distal esophagus.
    Leers JM; DeMeester SR; Chan N; Ayazi S; Oezcelik A; Abate E; Banki F; Lipham JC; Hagen JA; DeMeester TR
    J Thorac Cardiovasc Surg; 2009 Sep; 138(3):594-602; discussion 601-2. PubMed ID: 19698841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysphagia is not a Valuable Indicator of Tumor Response after Preoperative Chemotherapy for R0 Resected Patients with Adenocarcinoma of the Gastroesophageal Junction.
    Strandby RB; Svendsen LB; Bæksgaard L; Egeland C; Achiam MP
    Scand J Surg; 2016 Jun; 105(2):97-103. PubMed ID: 26250355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical study of modified Ivor-Lewis esophagectomy plus adjuvant radiotherapy for local control of stage IIA squamous cell carcinoma in the mid-thoracic esophagus.
    Chen G; Wang Z; Liu XY; Zhang MY; Liu FY
    Eur J Cardiothorac Surg; 2009 Jan; 35(1):1-7. PubMed ID: 18926712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?
    Yu E; Dar R; Rodrigues GB; Stitt L; Videtic GM; Truong P; Tomiak A; Ash R; Brecevic E; Inculet R; Malthaner R; Vincent M; Craig I; Kocha W; Lefcoe M
    Radiother Oncol; 2004 Nov; 73(2):141-8. PubMed ID: 15542160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.